4 Pages
English

Frost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market

Gain access to the library to view online
Learn more

Description

Frost & Sullivan: Strong Pipeline ofFrost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market PR Newswire LONDON, Jan. 29, 2014 - The market is expected to soar from $1.

Subjects

Informations

Published by
Published 29 January 2014
Reads 6
Language English
Frost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market

PR Newswire

- The market is expected to soar from $1.2 billion of 2013 to $24 billion in 2019

The imminent entry of several companies, including big pharma, small biotech and generic participants, into the global biosimilars space will propel the market towards exponential growth. Already, Indian groups such as Dr. Reddy's Laboratories, Biocon and Reliance Life Sciences are making a concerted effort to enter the European market. Although these companies have not yet penetrated the European market due to the stringent regulatory pathway, new product launches are expected in the mid-term.